Skip to main content
Premium Trial:

Request an Annual Quote

Gualberto Ruano, Richard Judson

Premium

Genaissance Pharmaceuticals CSO Gualberto Ruano will resign from the company on Aug. 31. Ruano, who was ousted from the chief executive’s slot one year ago, will also leave Genaissance’s board of directors. Richard Judson will replace him as CSO.

Judson, 44, joined Genaissance in 1999. Since August 2000 he has served as senior vice president of medical affairs and informatics, and had been responsible for leading the development of the company’s HAP Technology.

He came to Genaissance from CuraGen, where he managed the development of software for protein-protein interactions and DNA-sequence analysis.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.